Abstract

Introduction Cognitive fatigue is one of the most common and difficult to treat symptoms affecting patients with Multiple Sclerosis (MS). Previous studies suggested structural and functional abnormalities in the frontal cortex, especially a frontal hypo-activation, as a possible substrate for fatigue. Fatigue severity can be quantified by prolonged reaction times (RT) in alertness tests accompanied by lower amplitudes of the P300 event-related potential. Objectives In the present study we investigated whether neuromodulation of the left dorsolateral prefrontal cortex (DLPFC) by means of transcranial direct current stimulation (tDCS) has influence on electrophysiological and behavioral correlates of cognitive fatigue in MS. Materials and Methods: 15 MS patients with cognitive fatigue symptoms were enrolled in the study. In two sessions they were either stimulated with anodal tDCS (1.5 mA, 25 min) or sham stimulation over the left DLPFC. To assess fatigue severity, P300 during an auditory oddball task and performance on a simple reaction time test were recorded at baseline, during and after stimulation. Results Analysis revealed a significant stimulation effect on the P300 component. Compared to baseline, anodal but not sham tDCS caused an increase in P300 amplitude that persisted after the end of stimulation. In addition, anodal tDCS significantly attenuated the fatigue-related increase in RT over the course of a testing session. Conclusion Our findings demonstrate that a single dose of anodal tDCS over the left DLPFC has positive effects on electrophysiological and behavioral correlates of cognitive fatigue. In accordance with previous studies that showed a subjective fatigue relief by repeated stimulation sessions, our findings give important insight into the potential underlying mode of action of tDCS. The results provide causal evidence for a functional relevance of the left DLPFC in the pathogenesis of cognitive fatigue and show that tDCS-induced modulations of frontal activity can be a promising therapeutic option for the treatment of MS-related fatigue.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.